FUNDAMENTALS · Fundamentals · India Healthcare

Vijaya Diagnostic Centre (VIJAYA) Fundamentals 2026 — P/E 78.0x, Revenue Analysis | SniperIQ

Vijaya Diagnostic Centre (VIJAYA) is a India-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ₹13,493 Crore, trading at ₹1312.00 on the BSE. This SniperIQ fundamentals page covers Vijaya Diagnostic Centre's valuation (P/E 78.0x, P/B 14.1x), profitability (net margin 21.2%), revenue (₹814 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₹13,493 Crore
P/E (TTM)78.0x
Net Margin21.2%
Revenue (FY26)₹814 Crore

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Vijaya Diagnostic Centre's market cap?

Vijaya Diagnostic Centre (VIJAYA) has a market capitalization of approximately ₹13,493 Crore, trading at ₹1312.00 on the BSE. Market cap moves with the live share price.

What is Vijaya Diagnostic Centre's P/E ratio?

Vijaya Diagnostic Centre's trailing twelve-month P/E ratio is 78.0x, with a price-to-book (P/B) of 14.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Vijaya Diagnostic Centre?

Vijaya Diagnostic Centre runs a net profit margin of 21.2%, a gross margin of 81.7%, and an operating margin of 30.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Vijaya Diagnostic Centre generate?

Vijaya Diagnostic Centre reported revenue of ₹814 Crore for fiscal year 2026, with net income of ₹173 Crore and earnings per share (EPS) of 16.81. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Vijaya Diagnostic Centre pay a dividend?

Vijaya Diagnostic Centre offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Vijaya Diagnostic Centre financially healthy?

Vijaya Diagnostic Centre carries a debt-to-equity ratio of 0.44x and a current ratio of 2.60x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Vijaya Diagnostic Centre a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vijaya Diagnostic Centre (VIJAYA) the key facts are: market cap ₹13,493 Crore, P/E 78.0x, revenue ₹814 Crore, 52-week range 847.9-1440. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Vijaya Diagnostic Centre's full fundamentals live

Get Vijaya Diagnostic Centre's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Dongwha Pharm.Co (000020) fundamentals · Concord Biotech (CONCORDBIO) fundamentals · CVS Health (CVS) fundamentals · BML (4694) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons